The rising cost of drugs is more worrisome to most Americans than problems with Obamacare. Could proposals in California and Ohio help?
Why drug maker Mylan's decision to introduce a half-price version of its EpiPen could be more than a publicity stunt.
The maker of the EpiPen has raised the price of two injectable treatments to about US$600, six times the price nine years ago. Why do drug companies do this? Because they can. The FDA ends up helping.